After the UK’s withdrawal from the European Union took place, the UK regulatory context separated from that of the European Union, what posed a challenge for pharmaceutical companies in order to understand to what extent their market activity would be affected.
This change led to the need of providing support both for adapting past casuistries to the new regulatory environment and to generate strategic projects for new commercialization, such as in:
Altogether, these services are provided based on the following aspects:
After the UK’s withdrawal from the European Union took place, the UK regulatory context separated from that of the European Union, what posed a challenge for pharmaceutical companies in order to understand to what extent their market activity would be affected.
This change led to the need of providing support both for adapting past casuistries to the new regulatory environment and to generate strategic projects for new commercialization, such as in:
Altogether, these services are provided based on the following aspects:
UK Regulatory Affairs Services Solutions
Schedule a free meeting!
Discuss your case with our experts and receive a valuable feedback
Share
Why Asphalion?
Asphalion is fully prepared and experienced in acting as a local UK support to successfully manage your relationship with government and medical entities (MAH, MHRA, among others). As such, our experts are aware of the post-Brexit new regulatory requirements.
In fact, Asphalion counts with an office in the United Kingdom to help manage potential key contacts with regulatory entities to facilitate any administrative issue related to clinical development, registration, commercialization and adequate product maintenance.
Services
Memberships
Quality Management System
© Asphalion
Schedule here a free 30-minutes meeting with one of our consultants and tell us about your project, challenges or doubts.
We will be happy to assist you!
